| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Director | Vice Chairman +1 more
4 companies
Michael Severino is Chief Executive Officer at SRPT and has filed Form 4s across 4 companies. Michael Severino's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $59.4M at current prices.
Historically, Michael Severino's trades have earned a strong insider score of 70/100 across 6 rated trades. Over a 12-month horizon, all 6 of those trades were profitable, with an average 12-month return of +2.9%.
The biggest single holding is ABBV (~$43.5M) as Vice Chairman. The ABBV filings lean toward selling, a net 748,756 shares.
Michael Severino has 34 Form 4 filings on record from February 2015 to July 2026, across 4 companies: Chief Executive Officer at Sarepta Therapeutics (SRPT), 2026; Director at Avantor (AVTR), 2021–2026; Director at Viatris (VTRS), 2025–2026, and 1 more.
The 87 reported transactions were 30 stock awards, 22 open-market sales, 15 option exercises and 10 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 7 sales worth about $104.3M.
The largest open-market sale was 300,000 shares of ABBV at an average $151.12 on May 10, 2022, about $45.3M. Twelve months later ABBV was down 2%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 23, 2022 | ABBV Abbvie Inc. | Vice Chairman | Sale+OE | 79,801 | $150.90 | $12,041,780.49 | -34.4% | -4.3% | -1.8% | |
| May 17, 2022 | ABBV Abbvie Inc. | Vice Chairman | Sale+OE | 200,000 | $154.25 | $30,849,488.26 | -56.8% | -7.2% | -5.6% | |
| May 10, 2022 | ABBV Abbvie Inc. | Vice Chairman | Sale+OE | 300,000 | $151.12 | $45,336,287.56 | -66.4% | -6.9% | -1.8% | |
| Nov 4, 2020 | ABBV Abbvie Inc. | Vice Chairman | Sell | 90,679 | $93.61 | $8,488,461.19 | -57.4% | - | - | |
| Aug 17, 2018 | ABBV Abbvie Inc. | EVP, R& D and CSO | Sell | 50,000 | $97.52 | $4,876,060.28 | -37.8% | - | - | |
| Feb 28, 2018 | ABBV Abbvie Inc. | EVP, R& D and CSO | Sell | 2,643 | $117.93 | $311,683.70 | -2.0% | - | - | |
| Nov 10, 2017 | ABBV Abbvie Inc. | EVP, R& D and CSO | Sell | 25,633 | $94.69 | $2,427,211.84 | -18.2% | - | - |